| Title: |
Effect of semaglutide on COVID-19 and other infections: an analysis from the FLOW randomized clinical trial |
| Authors: |
Rayner, Brian; Mahaffey, Kenneth W; Mann, Johannes F E; Pratley, Richard E; Rossing, Peter; Belmar, Nicolas; Bosch-Traberg, Heidrun; Jeppesen, Ole Kleist; Tran, Minh Chau; Chernin, Gil; Tuttle, Katherine R |
| Contributors: |
Novo Nordisk |
| Source: |
Nephrology Dialysis Transplantation ; ISSN 0931-0509 1460-2385 |
| Publisher Information: |
Oxford University Press (OUP) |
| Publication Year: |
2026 |
| Description: |
Background In the FLOW trial (Evaluate Renal Function with Semaglutide Once-Weekly; ClinicalTrials.gov, NCT03819153), once-weekly subcutaneous semaglutide 1.0 mg versus placebo reduced the risk of major kidney, cardiovascular (CV) and mortality outcomes in participants with type 2 diabetes (T2D) and chronic kidney disease (CKD). This pre-specified analysis assesses the impact of semaglutide on risks of serious infections and coronavirus disease 2019 (COVID-19) in the FLOW trial. Methods The main outcome was a three-component composite [time from randomization to first infection serious adverse event (SAE), first hospitalization due to infection, or all-cause death]. Other outcomes included all infection SAEs, COVID-19 adverse events, COVID-19 SAEs, death due to infection and death concurrent with a COVID-19 SAE. Results Semaglutide reduced the risk of the main outcome versus placebo [hazard ratio (HR) (95% confidence interval) 0.79 (0.69–0.89); P = .0002]. This risk reduction was greater in subgroups with baseline hemoglobin A1c >8% [HR 0.63 (0.52–0.76)] versus ≤8% [HR 0.93 (0.79–1.11); Pinteraction = .0027], and urine albumin-to-creatinine ratio (UACR) ≥2000 mg/g [HR 0.53 (0.39–0.72)] versus UACR |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1093/ndt/gfag036 |
| DOI: |
10.1093/ndt/gfag036/67073037/gfag036.pdf |
| Availability: |
https://doi.org/10.1093/ndt/gfag036; https://academic.oup.com/ndt/advance-article-pdf/doi/10.1093/ndt/gfag036/67073037/gfag036.pdf |
| Rights: |
https://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.212FCFC9 |
| Database: |
BASE |